19.05.2025 • News

IMCD to Acquire Tecom Ingredients

IMCD has signed an agreement to acquire 100% of the shares in Tecom Ingredients.

Leaders of Tecom and IMCD
From left to right: Jose Alcover, Managing Director IMCD Iberia & Maghreb, Gemma Fernández, Finance Director Tecom, Fenna van Zanten, Director M&A and member of IMCD Group’s Executive Committee, Dolors Galofré, Co-Founder Tecom, Sixto Yáñez, Commercial Director and Co-Founder Tecom, Alberto Lastra, Finance Director IMCD Spain
© IMCD

IMCD, a partner for distributing and formulating specialty chemicals and ingredients, has signed an agreement to acquire 100% of the shares in Tecom Ingredients.

Founded in 1996 and headquartered in Molins de Rei, near Barcelona, Spain, Tecom is a recognised distributor of ingredients and additives to the food industry. The company serves the food and nutrition market in Iberia, developing innovative, high-quality solutions for savoury, bakery and pastry, dairy and plant-based beverages, confectionery, meat and ready meals, as well as health and nutrition.

“This acquisition enhances our presence in Iberia and expands our portfolio with ingredients that are highly complementary to our current offering,” said José Alcover, Managing Director of IMCD Iberia & Maghreb. “We’re thrilled to welcome a talented team with deep expertise in market-specific food applications.”

Sixto Yañez, Commercial Director and Co-Founder of Tecom added: “Joining IMCD marks an exciting new phase in our journey. We are bringing together two companies that share a strong culture of innovation, service, and long-term partnerships. This step opens up new avenues for growth and will allow us to offer even greater value to our customers.”

The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025.

Company

Logo:

IMCD Group B.V.

Wilhelminaplein 32
3072 Rotterdam
Netherlands

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.